Generic drugs are 30% to 80% cheaper than brand-name drugs, and they account for 88% of all U.S. prescriptions. But 4,300 generic drugs are still awaiting approval, and this backlog is costing consumers. Some of these generics have just entered the system, but some go back to 2009, which is before a program was implemented to help speed up the approval process. FDA has taken steps to improve the process, but generic drug companies still bemoan the slow progress. The agency claims that part of the problem is that drug makers submit applications that lack crucial information pertaining to research and patent protection. Drug makers, meanwhile, complain that FDA's changing standards for approval make the process inefficient.